Daxor Corporation (DXR) AI Stock Analysis

Daxor Corporation is a medical device company based in Oak Ridge, Tennessee, specializing in blood volume measurement technology. Its primary offering is the BVA-100 Blood Volume Analyzer, an instrument that delivers objective quantification of blood volume status and composition. This diagnostic tool enables healthcare professionals to evaluate and manage patient blood volume across surgical and medical settings. Originally incorporated in 1971 as Idant Corporation, the firm changed its name to Daxor Corporation in May 1973. The company aims to assist clinicians in tailoring treatment plans by comparing blood volume measurements against patient-specific norms.

Daxor Corporation has experienced volatile top-line results across recent periods. Revenue climbed from $5.8M in FY2021 to $6.3M in FY2022, then peaked at $34.6M in FY2023 with a 448.2% expansion. Revenue subsequently fell 93.8% to $2.1M in FY2024 and declined 76.4% to $503,424 in FY2025. Gross margin contracted to 37.5% in FY2025 from 100.0% in FY2024, yet net income totaled $9.2M in FY2025 due to an operating margin of 1824.7%. For the trailing twelve months ended June 30, 2026, revenue stood at $31,360 with an operating margin of -4529.9%. In the latest quarter, quarterly revenue grew 25.5% year-over-year while quarterly earnings rose 329.3%.

As of June 30, 2026, Daxor Corporation held $5.8M in cash and short-term investments, supporting total assets of $51.9M and shareholders' equity of $51.8M. Operating cash flow was negative across most recent years, recording -$604,420 in FY2025 and -$3.7M in FY2023, alongside identical free cash flow figures of -$604,420 and -$3.7M. The company did generate positive operating cash flow of $25,692 in FY2024. Over a five-year period, Daxor's share count was reduced by 38.3%.

Trading at a last close of $10.05 on October 16, 2026, Daxor Corporation carries an enterprise value of $42.9M and an EV-to-revenue multiple of 8.3x. Its trailing price-to-earnings ratio is 9.1x, below the 24.6x median of its US-listed Healthcare peers. However, its forward P/E multiple of 64.5x stands well above the US-listed Healthcare peer median of 17.3x. Daxor's price-to-book ratio sits at 1.2x. Over the past year, the stock returned -22.7%, lagging the 16.8% return for the S&P 500 benchmark.

Daxor Corporation carries 1 Strong Buy rating, 1 Buy rating, and no Hold or Sell ratings. The mean analyst price target is $20.00, representing a 99.0% premium over the October 16, 2026 close of $10.05. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $9.3M and an EPS of -$0.21. For the next fiscal year, one analyst estimates revenue will reach $16.4M, with revenue growth of 76.3% and an EPS of -$0.03. Daxor recorded 1 EPS beat over the last 4 quarters.

This page is an AI-written research summary of Daxor Corporation (DXR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: DXR income statement, DXR balance sheet, DXR key metrics, DXR analyst forecast, DXR chart. See the DXR stock overview for the latest quote and news.